Market Overview

Benzinga's M&A Chatter for Wednesday July 27, 2016

Share:

The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday July 27, 2016:

 

Sequenom Being Acquired by Lab Corp for $2.40/Share in Cash

The Deal:
Laboratory Corporation of America Holdings (NYSE: LH) and Sequenom, Inc. (NASDAQ: SQNM) announced Wednesday, that they have entered into a definitive agreement aunder which LabCorp would acquire all of the outstanding shares of Sequenom in a cash tender offer for $2.40 per share, for an equity value of $302 million.

The closing of the acquisition is expected by year end.

Sequenom closed at $2.40 on Wednesday, up 77%.

 

SABMiller Ordered Halt of AB InBev Integration Effort

The Rumor:
SABMiller Plc (OTC: SBMRY) is said to have suspended work on integrating the brewer’s operations with that of Anheuser-Busch InBev (NYSE: BUD), according to a memo seen by Bloomberg on Wednesday. In the memo, SABMiller CEO Alan Clark told employees “there should be no contact with AB InBev with immediate effect,” while a new offer is reviewed.

 

AB InBev and SABMiller declined to comment on the report,

On Tuesday, AB InBev made a revised and final all-cash offer of £45 per share for the entire issued and to be issued share capital of SABMiller.

Anheuser-Busch InBev closed at $121.94 on Wednesday, down 3.68%.

 

FTC Approves Teva-Allergan Deal

The Approval:
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) and Allergan plc (NYSE: AGN) announced Wednesday, that the U.S. FTC has accepted the proposed consent order in connection with the pending acquisition of Allergan's generics business by Teva. Thus, Teva has satisfied the regulatory approval requirements under the purchase agreement to complete the acquisition of Actavis Generics.

 

Teva closed Wednesday at $55.16, up 1.57%. Allergan Rose 4.54% to close at $260.24.

 

Related Articles (AGN + BUD)

View Comments and Join the Discussion!

Posted-In: M&A News Rumors Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com